Formulation and Evaluation of Fast Dissolving Tablet of Lisinopril

Orodispersible tablets are useful in patients, such as pediatric, geriatric, bedridden or developmentally disabled, who may face difficulty in swallowing conventional tablets or capsules and liquids orals or syrup, leading to ineffective therapy, with persistent nausea, sudden episodes of allergic attack or coughing for those who have an active life style. Fast onset of action- dispersible tablet has major advantage that the drug product is already in solution at that time it is consumed. Thus the absorption is faster and more complete than with conventional tablet. Lisinopril {(S)-1-[N2-(1-carboxy-3-phenylpropyl)-L proline] dihydrate} is a lysine analog of enalapril at, the active metabolite of enalapril. It is a long-acting, non sulfhydryl angiotensin-converting enzyme (ACE) inhibitor that is used for the treatment of hypertension and congestive heart failure in daily dosages of 10-80 mg.  All the superdisintegrants such as crosscarmellose, crosspovidone, sodium starch glycolate were maintained in different concentrations in all the formulations. Microcrystalline cellulose was used as diluent. Here microcrystalline cellulose was also a superdisintegrant; each formulation was composed of drug and excipients in various proportions. This design techniques was used to optimized and obtain better formulation with respect to in vitro dispersion time , Drug release (% ), Disintegration time. In vitro drug release showed that formula C- 5 (Crosspovidone) and S6 (sodium starch glycolate) had better % drug release as compare to other formulations. The faster disintegration may attribute to its rapid capillary activity and pronounce hydration with little tendency to gel formation. Thus these results can suggest that the disintegration time can be decreased by using wicking type of disintegrants.